论文部分内容阅读
[目的]比较不同联合用药方案在急性脑梗死中的效果。[方法]选取2008年1月～2011年1月于某院进行治疗的78例急性脑梗死患者为研究对象,将其随机分为A组(依达拉奉联合奥扎格雷组)39例和B组(依达拉奉联合丹参组)39例,后将两组患者的治疗总有效率、不良反应发生率及治疗前、治疗后7d、14d的NIHSS评分、血清CRP、Hcy、SOD、MDA水平进行统计及比较。[结果]A组的治疗总有效率高于B组,NIHSS评分优于B组,血清CRP、Hcy、MDA水平低于B组,SOD高于B组,P﹤0.05或P﹤0.01,有显著性差异或有非常显著性差异,但两组不良反应发生率差异无统计学意义,P﹥0.05。[结论]依达拉奉联合奥扎格雷治疗急性脑梗死疗效更佳,安全性也较高,可在急性脑梗死患者中应用。
[Objective] To compare the effect of different combination regimens in acute cerebral infarction. [Methods] A total of 78 patients with acute cerebral infarction who were treated in a hospital from January 2008 to January 2011 were selected and randomly divided into group A (edaravone plus ozagrel group) and control group Group B (Edaravone and Salvia Miltiorrhiza) 39 cases, the total effective rate of the two groups of patients, the incidence of adverse reactions and before treatment, NIHSS score 7d, 14d after treatment, serum CRP, Hcy, SOD, MDA Level statistics and comparison. [Result] The total effective rate of treatment in group A was higher than that in group B, the NIHSS score was better than that in group B, the levels of CRP, Hcy and MDA in serum were lower than those in group B, and SOD was higher than that in group B (P <0.05 or P <0.01) There was no significant difference between the two groups in the incidence of adverse reactions, P> 0.05. [Conclusion] Edaravone combined with ozagrel in the treatment of acute cerebral infarction has better curative effect and higher safety. It can be used in patients with acute cerebral infarction.